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Abstract
Introduction: Catheter-related bloodstream infections (CRBSIs) associated with short-term central venous catheters
(CVCs) in intensive care unit (ICU) patients are a major clinical problem. Bacterial colonization of the skin at the CVC
insertion site is an important etiologic factor for CRBSI. The aim of this study was to assess the efficacy of medical-
grade honey in reducing bacterial skin colonization at insertion sites.
Methods: A prospective, single-center, open-label randomized controlled trial was performed at the ICU of a
university hospital in The Netherlands to assess the efficacy of medical-grade honey to reduce skin colonization of
insertion sites. Medical-grade honey was applied in addition to standard CVC-site dressing and disinfection with
0.5% chlorhexidine in 70% alcohol. Skin colonization was assessed on a daily basis before CVC-site disinfection. The
primary end point was colonization of insertion sites with >100 colony-forming units at the last sampling before
removal of the CVC or transfer of the patient from the ICU. Secondary end points were quantitative levels of
colonization of the insertion sites and colonization of insertion sites stratified for CVC location.
Results: Colonization of insertion sites was not affected by the use of medical-grade honey, as 44 (34%) of 129
and 36 (34%) of 106 patients in the honey and standard care groups, respectively, had a positive skin culture (P =
0.98). Median levels of skin colonization at the last sampling were 1 (0 to 2.84) and 1 (0 to 2.70) log colony-forming
units (CFUs)/swab for the honey and control groups, respectively (P = 0.94). Gender, days of CVC placement, CVC
location, and CVC type were predictive for a positive skin culture. Correction for these variables did not change the
effect of honey on skin-culture positivity.
Conclusions: Medical-grade honey does not affect colonization of the skin at CVC insertion sites in ICU patients
when applied in addition to standard disinfection with 0.5% chlorhexidine in 70% alcohol.
Trial registration: Netherlands Trial Registry, NTR1652.
Introduction
Central venous catheters (CVCs) are indispensable for
the treatment of critically ill patients. Intensive care unit
(ICU) patients frequently have catheter-related blood-
stream infections (CRBSIs), a complication with high
morbidity and mortality, and increased resource utiliza-
tion [1]. Based on a conservative estimate, the total
extra costs attributable to CRBSIs are almost $1 billion
every year in the United States alone [2,3].
CRBSIs are caused mostly by bacteria originating from
the skin at CVC-insertion sites [4,5]. Coagulase-negative
staphylococci, Staphylococcus aureus, enterococci, and
various Gram-negative bacteria are responsible for the
majority of CRBSI episodes in critically ill patients [6].
Despite routine disinfection, approximately 30% of
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insertion sites become colonized [4,5,7]. Prophylactic
use of topical antibiotics has the potential to reduce the
colonization of catheter-insertion sites and thereby to
reduce the incidence of CRBSIs [8], but its large-scale
use is strongly discouraged because of the increased risk
of resistance development [6]. Therefore, alternative
antimicrobial strategies to reduce colonization of inser-
tion sites are urgently needed.
Honey has been used as an antimicrobial preparation for
thousands of years for treatment of wounds and preven-
tion of infections. Clinical investigations in mild- to mod-
erate-burn patients show that honey strongly reduces
bacterial colonization of the skin and accelerates wound
healing compared with silver sulfadiazine treatment [9,10].
As honey exerts its bactericidal activity by various
mechanisms, the risk for resistance development may be
considered negligible [11]. Revamil is a CE-marked, g-irra-
diated medical-grade honey with potent in vitro bacterici-
dal activity against a broad spectrum of antibiotic-resistant
bacteria. The bactericidal activity of this honey is based on
its high sugar concentration, the presence of hydrogen
peroxide produced in diluted honey by the glucose oxidase
enzyme, the antimicrobial peptide bee defensin-1, methyl-
glyoxal, and the low pH [12].
Because Revamil effectively reduces skin colonization
in healthy human volunteers [13], we hypothesized that
application of this honey could reduce skin colonization
at catheter insertion sites in critically ill patients. In a
randomized controlled trial, we assessed the efficacy of
daily topical application of this medical-grade honey to
reduce skin-culture positivity at the insertion sites of
ICU patients.
Materials and methods
Ethical approval and informed consent
The Medical Ethics Committee of the Academic Medi-
cal Center, Amsterdam, The Netherlands, reviewed and
approved the study protocol. The trial was registered at
The Netherlands Trial Registry (NTR number 1652).
Informed consent was obtained from all patients or
their next of kin before inclusion into the study.
Patients
The study was performed at the ICU of the Academic
Medical Center, Amsterdam, The Netherlands. Patients
were eligible if they had a CVC in situ for less than 48
hours that was inserted in the ICU, in the operating
theater, or in an emergency department with all appro-
priate sterile barriers. Only patients with an expected
ICU stay of >48 hours were eligible for participation.
Patients with skin disorders associated with an increased
risk of skin colonization, patients using long-term
immunosuppressive medication, pregnant patients, and
moribund patients were excluded.
Randomization
A randomization list was generated by using ALEA soft-
ware with a coin-bias factor of 5 and a biased-coin
threshold of 2. Allocation was concealed by using num-
bered envelopes. The details of the allocations were
unknown to any of the investigators.
Medical-grade honey
For the honey-treated group, the entire content of a syr-
inge containing 2 g of Revamil (Bfactory Health Pro-
ducts, Rhenen, The Netherlands) was applied to the
gauze CVC dressing.
Study protocol
The study was a prospective, open-label, randomized
controlled trial. After informed consent was obtained,
the first newly inserted catheter was included in the
study. Inclusion of only one CVC per patient was per-
mitted in this study. Patients who were enrolled were
randomly assigned to treatment with honey or standard
catheter care. At inclusion, the skin surrounding the
insertion site was disinfected, according to standard pro-
cedures, with 0.5% chlorhexidine in 70% alcohol. A ster-
ile gauze dressing with or without honey was applied to
the insertion site, and the gauze was covered with a
transparent Tegaderm dressing (3M Health Care, St.
Paul, MN, USA).
During the entire study period, an area of approxi-
mately 3 × 3 cm of the skin at the insertion site was
sampled daily with a cotton swab moistened with sterile
normal saline. Moistened cotton swabs are a commonly
used method to determine the level of skin colonization
[7,14-17]. Subsequently, the skin was disinfected accord-
ing standard procedures, as described earlier, and new
gauze with or without honey was applied. This proce-
dure was continued either until the CVC was removed,
until the patient was discharged from the ICU, or until
the patient died, whichever came first.
Microbiologic analysis
After sampling of the skin, the tip of the cotton swab
was transferred to a 1.5-ml tube containing 0.5 ml of
sterile saline. The tube was sonicated in a waterbath for
30 seconds and subsequently vortexed for 10 seconds.
The cotton tip was removed, and the sonicate was quan-
titatively cultured on blood agar plates at 37°C for 2
days.
Primary and secondary end points
The primary outcome was colonization of skin sur-
rounding the insertion site with >100 CFU/swab at the
last sampling. Such a level of skin colonization during
catheter use is a major risk factor for CRBSI [15,17,18].
Secondary outcomes were the level of colonization at
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the last sampling and stratification of these outcomes by
catheter location, duration of catheter stay, ICU length
of stay, and ICU and hospital mortality.
Microbial identification
Microorganisms cultured from the skin of patients with
a positive primary end point were identified by using
VITEK-2 (BioMérieux, Boxtel, the Netherlands) and
classic biochemical determination. We also collected
clinical microbiologic data of culture-positive blood
samples from patients taken during their inclusion in
the study. Blood samples were drawn only for clinical
diagnosis and not for study purposes.
Power calculation
We aimed for a clinically relevant reduction in skin-
colonization frequency of 50%, which, based on available
literature, meant a reduction from 30% to 15% culture
positivity [4,5,7]. A two-group c2 test with a 0.050 two-
sided significance level and an 80% power to detect the
difference between a Group 1 proportion of 0.3 and a
Group 2 proportion of 0.15 required a sample size of
120 patients for each group.
Statistical analysis
Continuous normally distributed variables were
expressed by their mean and standard deviation or,
when not normally distributed, as medians and their
interquartile ranges. Categoric variables were expressed
as n (%). To test groups, Student t tests were used; if
continuous data were not normally distributed, the
Mann-Whitney U test was used. Categoric variables
were compared with the c2 or Fisher Exact tests.
In addition, we aimed to quantify the net effect of the
application of medical-grade honey on the colonization
of insertion sites, controlling for other variables.
Exploration of interaction (effect modification) and con-
founding was considered methodologically relevant for
this approach. Therefore, we first focused on the crude
(uncorrected) effect of honey (independent variable) on
colonization (dependent variable). Then statistical and
clinically relevant covariates were added as an interac-
tion term. If the interaction term appeared to be signifi-
cant (P < 0.05), this would indicate that the relation
between the honey and colonization could be different
for various levels of the covariate. This indicates the
need for separate models for the levels of the covariate.
As a significant interaction was not found, the model
was examined for confounding. Confounding was
defined as ≥10% change in the coefficient of the central
determinant (honey) as a consequence of adding a
covariate.
To analyze for an effect of honey or other variables on
the level of skin colonization over time, a mixed-model
repeated measures method was used to deal with unba-
lanced data due to different numbers of cultures per
patient and missing values. We used a random intercept
and random slopes model. Treatment group, catheter
type, and catheter location were fixed covariates.
Statistical significance was considered to be at P =
0.05. When appropriate, statistical uncertainty was
expressed by the 95% confidence levels. Analysis was
performed with SPSS version 18.2.
Results
Patients
In total, 242 patients were enrolled, of whom 133 and
109 were assigned to the honey and control group,
respectively (Figure 1). For seven participants (four in
the honey group and three in the control group), no
data were obtained, because these patients were lost to
follow-up before a skin swab was taken. Baseline charac-
teristics of evaluated patients are described in Table 1.
The effect of honey on skin colonization
All included catheters were sampled for the consecutive
days that the patients resided in the ICU. Culture results
for all samples of the honey and control group are pre-
sented in Additional file 1. In both the honey-treated
group and the control group, 34% of the patients had a
positive skin culture (defined as >100 CFUs) at the last
sampling point (Table 2). Median (IQR) levels of skin
colonization at the last sampling were 1 (0 to 2.84) and
1 (0 to 2.70) log CFU/swab for the honey and control
groups, respectively (P = 0.94). In the honey group,
more jugular catheters were included compared with
the control group, whereas in the latter group, more
femoral catheters were included (Table 1). However,
stratification according to CVC location did not reveal
significant differences in the percentage of positive skin
cultures or in quantitative levels of colonization between
the honey and control groups (Table 2).
Median ICU length of stay was 9 (4 to 18) and 9 (5 to
16) days for patients in the honey-treated and control
groups, respectively (P = 0.67). Median duration of
catheter use was 5 (3 to 7) days for both study groups
(P = 0.32). ICU mortality was 24% and 23% in the
honey and control groups, respectively (P = 0.88), and
total hospital mortality was 36% and 34% for the respec-
tive groups (P = 0.89). Reasons for removal of the CVC
were also not significantly different for both study
groups (Table 3).
Multivariate logistic regression was performed to
obtain insight into the role of baseline characteristics as
predictors of positive skin cultures. Duration of CVC
use, CVC location, CVC type, and gender appeared to
be statistically associated (P ≤ 0.10) with positive skin
cultures. We found no interaction effect of any of the
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covariates in multivariate analysis. Although the statisti-
cally associated covariates did qualify as confounders
(that is, adding these variables to the logistic model
changed the beta factor of the crude relation between
study group and positive skin cultures by more than
10%), the primary predictor (medical-grade honey)
remained nonsignificant (that is, OR, 1.01 (0.59 to 1.73);
P = 0.98.
A mixed-model repeated measures method was used to
assess whether a difference existed in the level of skin
colonization over time between the honey and control
groups. Honey did not have a significant effect on quanti-
tative level of skin colonization (P = 0.37). The duration of
catheter use significantly affected skin colonization; the
positive value of the regression coefficient showed that the
log CFU/swab count increased for successive samplings.
Furthermore, a significant increase was found in log CFU/
swab for single-lumen catheters over time (P = 0.03).
Catheters inserted at the subclavian site showed a signifi-
cant decrease in log CFU/swab over time (P = 0.01).
Microorganisms cultured from skin and blood
Coagulase-negative staphylococci (CoNSs) were the
most frequently isolated bacteria at insertion sites,
accounting for 62% and 60% of all isolated microorgan-
isms in the honey and control groups, respectively.
Enterococci were isolated in 30% of positive skin cul-
tures for both study groups. Streptococci, micrococci,
Klebsiella spp., and Pseudomonas spp. were responsible
for the remaining positive skin swabs. Eleven (16%) of
70 and six (13%) of 48 (P = 0.79) blood samples from
patients in the honey-treated and control groups,
respectively, were positive for microbial growth. In the
honey-treated group, seven blood cultures were positive
for CoNS, two for enterococci, one for both CoNS and
enterococci, and one for Staphylococcus aureus. In the
control group, three blood cultures were positive for
CoNS, one for both CoNS and enterococci, one for
Pseudomonas aeruginosa, and one for Candida glabrata
(control group).
Discussion
Daily application of Revamil medical-grade honey did
not reduce the frequency of positive skin cultures of
CVC insertion sites of critically ill patients. Gender,
duration of CVC use, CVC location, and CVC type were
predictive for a positive culture, which is in agreement
with several publications on independent risk factors for
474 patients were eligible 
242 included
80 no informed consent
152 patients excluded
• 28 renal transplant
• 29 stem cell transplant
• 77 chronic steroid use
• 8 skin disease
• 5 pregnant
• 5 imminent death
133 randomized to honey 109 randomized to conventional dressing
129 evaluated 106 evaluated
4 no evaluable data 3 no evaluable data
Figure 1 CONSORT flow diagram.
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catheter-site colonization and catheter-related infections
[15,18,19]. After correction for these variables, no effect
of honey on frequency of positive skin cultures was
detected in a multivariate logistic regression model. No
differences were observed in the secondary end points,
which were quantitative level of colonization of CVC
sites, microbiologic outcomes for different catheter
locations, ICU length of stay, duration of catheter use,
and ICU and hospital mortality.
Large-scale prophylactic application of antibiotics to
prevent CRBSIs is strongly discouraged because of the
risk for development of antibiotic resistance [6]. Because
no resistance against honey has ever been reported,
honey could be a very interesting alternative to antibio-
tics for topical applications. To the best of our knowl-
edge, the current study is the first in which honey as an
antimicrobial agent was applied to ICU patients.
Honey was previously applied to exit sites of tunneled,
cuffed, internal jugular CVCs by Johnson et al. [11].
These investigators showed that mupirocin significantly
reduced the frequency of catheter-related bacteremia
and increased time to first bacteremia for patients
undergoing hemodialysis carrying such catheters [20]. In
a follow-up study, they showed that insertion-site care
with a manuka honey (Medihoney; Medihoney Pty Ltd,
Brisbane, Australia) was as effective as mupirocin in
terms of rates of catheter-related bacteremia and infec-
tion-free survival time [11]. Although the latter study
was not adequately powered to demonstrate equivalence
between honey and mupirocin, the results indicate that
thrice-weekly application of Medihoney to tunneled,
cuffed hemodialysis catheters reduces the risk of cathe-
ter-related infections. This strongly suggests that the
applied honey reduced colonization of the catheter-
insertion sites.
Several differences between the present trial and the
study by Johnson et al. may explain the different effects
of honey. Whereas Johnson et al. studied the application
of Medihoney to the insertion site of surgically placed,
tunneled, cuffed catheters for long-term use in patients
with renal failure, we applied Revamil honey to the
insertion site of nontunneled, short-term CVC in criti-
cally ill patients. The modes of application of honey by
Johnson et al. and in our study were essentially the
same. They directly applied honey to the skin and cov-
ered it with a Primapore dressing consisting of an absor-
bent pad and a fixative layer. We applied honey on a
gauze dressing, placed the gauze on the catheter-inser-
tion site with the honey facing the skin, and covered the
gauze with a transparent plaster to keep it in place.
Whereas Johnson et al. studied hemodialysis outpati-
ents, we studied critically ill patients. Critical illness
Table 1 Baseline patient and catheter characteristics
Honey Control
Patients, n (%) 129 (54.9) 106 (45.1)
Male, n (%) 68 (53) 69 (65)
Age, mean (SD) 63 (14) 63 (15)
APACHE II score, mean (SD) 21 (7) 22 (7)
Admission type, n (%)
Medical 71 (56) 58 (55)
Surgical urgent 30 (23) 29 (27)
Surgical elective 27 (21) 19 (18)
Confirmed infection at admission, n (%) 32 (25) 26 (25)
Immunosuppressive medication, n (%) 7 (5) 6 (6)
Neutropenic, n (%) 8 (6) 3 (3)
Catheter location, n (%)
Femoralis 60 (46) 65 (61)
Jugularis 45 (43) 29 (27)
Subclavia 14 (11) 12 (11)
Catheter type
CVVH 32 (25) 26 (25)
Swan-Ganz 7 (5) 3 (3)
One lumen 0 2 (2)
Three lumens 88 (68) 72 (68)
Four lumens 1 (1) 0
CVVH with an extra lumen 1 (1) 2 (2)
Side port 0 1 (1)
Table 2 Skin-colonization outcomes
Honey n = 129 Control n = 106 P
value
Last culture positive, n
(%)
44 (34) 36 (34) 0.98
Log CFU/swab, median
(IQR)
1 (0-2.84) 1 (0-2.70) 0.94
Last culture, stratified for catheter location
Femoralis, n (%) 22 (37) 25 (38) 0.21
Jugularis, n (%) 20 (44) 10 (34) 0.17
Subclavia, n (%) 2 (14) 1 (8) 0.68
Log CFU/swab, stratified for catheter location
Femoralis, median (IQR) 1.3 (0-2.95) n =
60
1.30 (0-2.73) n =
65
1.0
Jugularis, median (IQR) 0 (0-3.2) n = 55 1 (0-2.7) n = 29 0.89
Subclavia, median (IQR) 0 (0-0) n = 14 0 (0-0) n = 12 0.90
Last culture is defined as the last sampling time point before catheter
removal, transfer of patient from the ICU, or death.
Table 3 Reasons for catheter removal
Honey n = 129 Control n = 106 P value
No longer needed, n (%) 54 (42) 39 (37) 0.42
Suspected infection, n (%) 20 (16) 15 (14) 0.77
Dysfunction, n (%) 5 (4) 4 (4) 0.97
Patient died, n (%) 19 (15) 18 (17) 0.64
Patient discharged, n (%) 31 (24) 30 (28) 0.46
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increases capillary permeability, often accompanied by
leakage of edema fluid along CVC insertion sites [21].
Indeed, we frequently observed absorption of large
amounts of exudate by the gauze. Due to this leakage of
fluid and the use of nontunneled catheters, the honey
applied in our study might have been more strongly
diluted than that in the study by Johnson et al. [11].
Differences between our trial results and those of
Johnson et al. may also lie in the compositions of the
honeys used. Honeys differ in their composition of anti-
microbial compounds, Revamil relying particularly on
hydrogen peroxide production and the antimicrobial
peptide bee defensin-1, and manuka honey, mostly on
methylglyoxal [22]. The activity of Revamil honey
against staphylococci and enterococci particularly
depends on hydrogen peroxide [12]. Hydrogen peroxide
is formed on dilution of honey. When Revamil honey is
diluted by wound exudate on application at catheter-
insertion sites, the hydrogen peroxide produced may
become degraded by catalase present in this exudate.
This could aggravate the loss of antibacterial activity of
Revamil honey on dilution. Because manuka-based hon-
eys like Medihoney, as used by Johnson et al., retain
activity up to higher dilutions than Revamil honey,
owing to high levels of methylglyoxal and other nonper-
oxide antimicrobial compounds, they are less prone to
lose activity because of dilution by wound exudate [22].
The combination of possible lower levels of exudation
in the study by Johnson et al. and the lower loss of
activity of Medihoney on dilution, may thus have
favored the outcome of their study. Therefore, honeys
that retain antibacterial activity up to high dilutions in
wound fluid might be more effective than honeys like
Revamil for applications at sites of high exudation.
In this study, we used moistened cotton swabs to assess
skin colonization. This is one of the most commonly
used methods to assess skin colonization [14,15,17,18].
We considered this method more appropriate than the
contact-plate method [23], because the contact-plate
method requires the sampled skin surface to be flat. This
was not the case in our study because of the presence of
the catheter and the anatomy of the jugular and femoral
catheter locations. Moreover, the very high level of cathe-
ter-site colonization, as observed for a substantial num-
ber of patients in our study, would have caused confluent
growth when using the contact plate method and would
thus have impeded quantification of the colonizing
microorganisms. Thus, skin sampling using moistened
cotton swabs was the method of choice in our study.
A level of colonization of approximately 100 CFU per 10
cm2 of skin cultured by using a moistened cotton swab is
frequently used to define positive skin cultures [14,15,17].
This level of colonization is actually reported as a major
risk factor for catheter-related bloodstream infection [18].
We therefore decided to define a level of 100 CFU as a
clinically relevant criterion for a positive skin culture.
We chose to perform daily dressing changes to allow
frequent replacement with fresh honey to maximize the
possibility to achieve an effective antibacterial treatment.
Daily dressing change, however, is not routinely per-
formed at our ICU. Guidelines regarding frequency of
dressing change and type of dressing to be used are still
under debate [18].
Maki and Ringer [24] showed that replacement of
gauze dressings every other day results in slightly lower
levels of colonization of catheter sites compared with a
situation in which the dressing remains in place for the
lifetime of the catheter; the differences in levels of skin
colonization between these dressing regimens were, how-
ever, only minute. The authors concluded that it would
not be cost effective to redress catheters at periodic inter-
vals. More recently, also for application of transparent
polyurethane dressings and for chlorhexidine-impreg-
nated sponges, it was shown that less-frequent catheter-
dressing changes do not increase the risk for catheter
infection, while significantly reducing patient discomfort
and costs [25,26]. On the basis of the studies described,
the CDC guidelines for prevention of catheter-infection
advise changing dressings at least every 7 days, but do
not advise against more-frequent dressing change [27].
The results of our trial, however, should be interpreted in
the context of daily dressing changes.
Several weaknesses exist in the design of our trial. Our
trial has limitations inherent to a single-center design.
Moreover, this trial was performed at an ICU by using
selective decontamination of the digestive tract (SDD)
[28,29]. The SDD regimen apparently did not substan-
tially affect microbial colonization of the skin at catheter-
insertion sites, because we identified mainly coagulase-
negative staphylococci and streptococci, bacterial species
typically found on skin. Therefore, this suggests that the
SDD regimen does not necessarily hamper extrapolation
of our results to other centers not using SDD.
Second, we used an open-label design. It was inevita-
ble to use an open-label design for this trial because no
proper placebo for honey is available. The absence of
blinding could have potentially introduced observer
biases. The risk for such bias was minimized by using a
clearly defined, objective outcome measure.
A substantial imbalance in numbers of patients was
randomized in the two study arms, 133 in the honey
group, and 109, in the control group. Such an imbalance
is a potential source of bias, especially covariate imbal-
ance. However, the highly comparable distribution of
potential confounders between groups (Table 1), as well
as the outcome of the multivariate logistic regression
model, sufficiently showed the absence of such bias.
Particularly the regression model demonstrated that
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neither effect modification nor confounding altered the
conclusion.
It was not feasible to use CRBSI as an end point,
because of its relatively low incidence. The reported
incidence of CRBSI in international studies varies from
1.4 to 7.7 episodes per 1,000 catheter days [6,30,31].
Even when based on the highest incidence within this
range, a sample size of about 14,000 catheter days
would be required to identify a 50% reduction in inci-
dence of CRBSI. Therefore, we used catheter-site coloni-
zation as a proxy for CRBSI, because colonization of the
catheter site, with >100 CFU/swab at catheter removal,
is a major risk factor for CRBSI [15,17,18]. Thirty per-
cent of the skin swabs of catheter-insertion sites of ICU
patients are reported culture positive [4,5,7]. The fre-
quency of culture-positive skin swabs in the control
group of our study was even somewhat higher (34%).
Thus, our study was sufficiently powered to detect a
50% difference in the frequency of positive skin cultures
between the study and control groups.
Conclusions
Honey did not reduce microbial skin colonization at the
insertion site of CVCs in ICU patients.
Key messages
• Revamil medical-grade honey does not reduce
microbial colonization around the insertion site of
nontunneled, short-term CVCs of ICU patients.
• The natural variation in presence of different anti-
bacterial compounds in honey might explain the
observed differences in clinical efficacy of honey
between our trial and a previous study by Johnson et
al. [11].
• Extensive characterization of the composition of
the bactericidal compounds is essential for applica-
tion of medical-grade honey as a topical antimicro-
bial agent in modern medicine.
Additional material
Additional file 1: Culture results for the honey and control group over
time. Catheter sites were sampled on a daily basis after inclusion of
patients in the study. The numbers of positive skin cultures (shaded) and
negative cultures (white) are indicated for the honey group (left bars)
and for the control group (right bars) for consecutive days (A), and the
levels of skin colonization for consecutive days are indicated for the
honey group (open circles) and for the control group (solid circles) in log
CFU/swab (B).
Abbreviations
CFU: colony-forming unit; CoNS: coagulase-negative staphylococci; CRBSI:
catheter-related bloodstream infection; CVC: central venous catheter; CVVH:
continuous veno-venous hemofiltration; ICU: intensive care unit; SDD:
selective decontamination of the digestive tract.
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